Clinical Trial: Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.

U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07213076) titled 'Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.' on Oct. 01.

Brief Summary: This is a retrospective, observational study of treatment patterns and clinical outcomes in Australian EGFRm advanced and metastatic non-small cell lung cancer patients treated with first-line osimertinib or second-line osimertinib.

Study Start Date: July 04

Study Type: OBSERVATIONAL

Condition: Non-small Cell Lung Cancer

Recruitment Status: RECRUITING

Sponsor: AstraZeneca

Disclaimer: Curated by HT Syndication....